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Abstract: One of many types of extracellular vesicles (EVs), exosomes are nanovesicle structures that
are released by almost all living cells that can perform a wide range of critical biological functions.
Exosomes play important roles in both normal and pathological conditions by regulating cell-cell
communication in cancer, angiogenesis, cellular differentiation, osteogenesis, and inflammation.
Exosomes are stable in vivo and they can regulate biological processes by transferring lipids, proteins,
nucleic acids, and even entire signaling pathways through the circulation to cells at distal sites. Recent
advances in the identification, production, and purification of exosomes have created opportunities
to exploit these structures as novel drug delivery systems, modulators of cell signaling, mediators of
antigen presentation, as well as biological targeting agents and diagnostic tools in cancer therapy. This
review will examine the functions of immunocyte-derived exosomes and their roles in the immune
response under physiological and pathological conditions. The use of immunocyte exosomes in
immunotherapy and vaccine development is discussed.
Keywords: exosome; immunocyte; immunoregulation; immunotherapy; natural killer cells
1. Introduction
Extracellular vesicles (EVs) are a heterogeneous family of lipid bilayer-derived nanovesicles that
are released by almost all living cells [1,2]. Exosomes, which represent one subpopulation of EVs, arise
from a unique biogenesis pathway and are characterized by a cup-shaped morphology under electron
microscopy a diameter of 30–100 nm and a density of 1.13–1.19g/mL [3].
The biogenesis of exosomes is a highly dynamic but ordered process. By inward budding of
plasma membrane, membrane-enclosed compartments called early endosomes (EEs) are created [4–6].
Subsequently, inward budding of EE membranes generates intraluminal vesicles (ILV) [7], a process
that is mediated by the endosomal sorting complex required for transport (ESCRT), tetraspanins,
and the lipid lysobisphosphatidic acid (LBPA) [8]. ILVs are loaded with cargo by capture during
vesicle formation or via a trans-golgi process regulated by CD2AP and LMAN2 [9] and mature into
late endosomes, or multivesicular bodies (MVB) [10], which fuse with either lysosomes for content
degradation or the plasma membrane to release exosomes into the extracellular environment [11–13].
Thus, the composition of exosomes is generally recognized as representative of their parental cells and
they are utilized as biomarkers of cellular function in vivo [14]. Although exosomes are characterized
primarily as vehicles for the elimination of cellular waste, they are also active players in diverse
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cellular functions [15], especially in the context of the immune system. Critically, exosomes are often
enriched in molecules associated with specific biological functions that can affect cells at distal sites
after release into the circulation. Exosomes transmit information and activate biological responses in
target cells through several potential mechanisms: 1. Direct fusion with the plasma membrane and
release of exosomal contents, 2. The uptake of intact exosomes into endosomes and subsequent release
of contents into the cytoplasm, and 3. Juxacrine signaling between ligands expressed on exosomes and
cognate receptors on target cells, without intracellular delivery of cargo [16,17].
The process of target cell recognition, uptake, and release of cargo is under investigation and the
molecular components are currently being identified and validated. The recognition and binding of
target cells by exosomes is not completely understood and it may be a largely non-specific stochastic
process, although there is evidence for the preferential uptake of certain exosomes by specific cell
types. Following initial contact, exosomes establish a point of entry into acceptor cells. This stage
might depend on relatively non-specific mechanisms such as macropinocytosis or micropinocytosis or
may be dependent on specific receptor-ligand interactions [13,17]. Several families of proteins have
been identified on the surface of exosomes„ such as T and B cell receptors, cytokines and cytokine
receptors, integrins, and lectins, which may provide specificity to this process. Following exosome
internalization, which is mediated through several different pathways, the contents of exosomes are
released by either direct fusion with the plasma membrane or via uptake as intact vesicles via the
endosomal pathway [17]. This distinction is particularly important in the context of antigen presenting
cells (APCs), which can process exosomal antigens through endosomes where they are loaded onto
MHC molecules and presented to effector lymphocytes, activating the immune response.
While the molecular nature of exosome-target cell interactions is still incompletely understood,
these findings suggest that at least some components of the recognition and entry process are
receptor-dependent and thus can be manipulated to increase the precision of exosome targeting. This
is of great interest therapeutically, as exosomes can be engineered genetically and pharmacologically to
express receptors that target specific cell types or tissues, which would enhance the specificity of their
target cell binding, increase their efficacy, and reduce deleterious off-target effects [18].
Through the processes of biogenesis and capture by acceptor cells, exosomes deliver proteins,
lipids, and a number of RNA species, including regulatory micro RNAs (miRNAs) from their cells of
origin, all of which are capable of modulating target cell function and gene expression [19–23].
Many studies have shown that immunocytes secrete exosomes [3,24], which act as immune
modulators in normal and disease conditions. Here, we review recent findings and highlight the
biological and pathophysiological functions of immunocyte-derived exosomes in immunoregulation
as well as their use in immunotherapy and vaccine development. We use the term exosome to describe
all vesicle structures of standard size (30–100 nm) that express typical exosomal markers.
2. Exosomes: Efficient Nano-Messengers of Antigen Presentation
In 1996, exosomes were first identified as nanovesicles that are enriched in major histocompatibility
complex class II (MHC-II) molecules secreted from B-lymphoblastoid cells [25]. Subsequently,
exosome-like structures were found to be associated with all types of immunocytes, including
B and T lymphocytes, macrophages, dendritic cells (DCs), natural killer (NK) cells, mast cells,
and thymocytes [3,24,26]. Molecular profiling of exosomes revealed the classical exosome markers, such
as intraluminal heat shock proteins, tetraspanins, multivesicular body (MVB) biogenesis proteins, as
well as lipid-related proteins and phospholipases, which are associated with exosome biogenesis [27–29].
Exosomes that are derived from immunocytes, however, were enriched in proteins with immunological
function, including antigen presenting molecules (MHC class I, MHC class II, and CD1), adhesion
molecules (CD11b, CD54/ICAM-1), and costimulatory proteins (CD86) [27,30]. The molecular profiles
of exosomes are thus similar to but distinct from those of their parental cells, which suggests that
they are designed to perform specialized biological functions [8]. Indeed, exosomes that are derived
from APCs and other immunocytes can present antigens to T cells and activate immune responses via
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classical MHC-restricted mechanisms, involving multiple cell-cell interactions. Exosomes function
in initial T cell priming, differentiation of mature T cells, and the development of effector functions.
Antigen presentation by exosomes can be accomplished by transfer of MHC-peptide complexes
between naïve dendritic cells, uptake and presentation of exosome cargo by mature DCs, as well as by
direct T cell activation without the need for uptake and further processing by APCs.
In addition to unique sets of proteins, the lipid composition of exosomes is also distinct
from other cellular membranes. Exosomal membranes are enriched in certain lipids, such as
sphingomyelin, lysophosphatidylcholine, and saturated fatty acids, but relatively poor in others,
such as phosphatidylcholine and diacylglycerol [31]. Cholesterol and ganglioside GM3 in exosome
membranes confer excellent detergent-resistance and the capacity for extended survival in the
extracellular environment [32]. In addition, proteins that protect them from degradation enhance the
stability of exosome membranes. Two molecules that inhibit complement-dependent membrane attack
and cell lysis, CD55 and CD59, were both found at high levels on exosomes that were derived from
human APCs and thus are likely to protect exosomes from complement-mediated destruction in the
plasma [33]. Likewise, the anti-phagocytic protein CD47 has been found on the surface of exosomes
from multiple cell types, including T lymphocytes. CD47 blocks macrophage-mediated uptake of
exosomes by engaging the Sirp-α inhibitory receptor, sending a “do not eat” signal, and preventing
destruction by phagocytosis [18]. Liposomes and exosomes lacking CD47 displayed reduced retention
in the circulation relative to CD47+ exosomes, which suggests that the enhanced in vivo stability of
exosomes is due in part to CD47-dependent inhibition of phagocytosis. The combination of specialized,
biologically active components and physical stability suggests that immunocyte exosomes are uniquely
suited as vectors for the transport of cargo, such as tumor antigens or therapeutic drugs through the
circulation to target cells in vivo.
B cells capture cell-free antigens via cell surface B-cell receptors (BCRs) and translocate them
into the endosomal pathway for processing in antigen presentation or release them as exosomal
cargo [34–36]. Recent studies have shown that B cell exosomes activate the immune response through
multiple mechanisms. They express high levels of MHC-I, MHC-II molecules, co-stimulatory molecules
and human leukocyte antigens (HLA), and induce antigen-specific T cell responses [25,37–39]. B-cell
exosomes were also found to contain integrins and ICAM-1 (CD54) that promote anchoring to
the extracellular matrix (ECM), and facilitate delivery of cargo to target cells through heterotypic
interactions with leukocyte function-associated antigen (LFA)-1 on lymphocytes. Hence, B cell exosomes
might penetrate tissues via interaction with the ECM and deliver immune cargo to pro-inflammatory
effector cells through specific receptor-ligand interactions [40]. Likewise, CD38, a glycoprotein with
glycohydrolase activity, was detected on human lymphoblastoid B cell-derived exosomes. This protein
is associated with membrane rafts in lymphocytes that contain signaling and co-stimulatory proteins,
such as CD81 and the Src-family kinase lyn, suggesting that they can act as intercellular messengers of
lymphocyte activation [41]. In a related study, Papp, et al. [42]. reported that murine macrophages and
B cells covalently fix C3 complement fragments to their cell membranes and release them on exosomes.
The engagement of exosome-bound C3+ by G protein-coupled receptor C3aR on T cells enhanced
T-cell responses in the presence of sub-threshold antigenic stimulation [42].
Dendritic cells (DCs) are the most potent APCs, and they can release up to one million MHC-II
molecules in 24 h via the DC-derived exosome (Dex) pathway [43]. Dex contain the machinery for
antigen presentation and they have been shown to activate T cell-mediated cytotoxicity through
engagement of T cell receptor (TCR) complexes, while adhesion molecules aid in targeted transfer of
exosomal cargoes to lymphocytes via interactions with LFA-1 [44]. Because of their stability in the
extracellular environment, Dex can activate T cells at distal sites, in the absence of intact APCs [45].
Segura, et al. reported that CD8+ DCs express high levels of LFA-1 and are therefore likely to internalize
Dex in vivo [46]. Thus, Dex-mediated antigen transfer might promote both MHC II-dependent classical
presentation by DCs as well as MHC I-dependent “cross-presentation” of exogenous antigens by CD8+
DCs. Likewise, CD4+ T cells are also able to engage MHC-II-containing Dex via a LFA-1-dependent
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mechanism [47], which suggests that Dex potentiate both T cell help and the development of cytotoxic
effector T cell function. These studies also demonstrated that Dex could acquire antigens either through
internalization and processing of antigens by DC or by direct capture of free antigens [48]. However,
recent findings suggest that prior processing of antigens is required for optimal exosome-mediated T
cell activation [49].
Exosomes have also been shown to participate in more complex communication among
components of the immune system. For example, Dex are a danger signal to the immune system in cases
of pathogen infection. Through capture and presentation of bacterial toll-like receptor ligands (TLR-Ls),
Dex stimulated bystander DCs to secrete tumor necrosis factor (TNF)-α and proinflammatory cytokines,
which in turn induced IFN-γ secretion by NK cells [50], activating the innate immune response. A recent
study demonstrated that T cells and APCs could reciprocally exchange exosomes. T cell exosomes
transferred miRNAs, such as miR-335 to DCs at the immune synapse, potentially modulating APC
gene expression [51]. Furthermore, regulation of the immune response by exosomes likely involves
interactions between multiple immune cell subpopulations. A recent study indicated that, in vivo,
the activation of cytotoxic T lymphocytes (CTLs) by B cell-derived exosomes was dependent on the
presence of CD4 T cells and NK cells, which suggests that exoxome-driven immune responses require
T cell help and cross-talk between immunocytes [52]. Likewise, it was shown that immune stimulation
by Dex was dependent on cross talk between CD4+ T cells and B cells. Such complex interactions
must be considered when using Dex as immune response modifiers in clinical applications [53].
According to recent studies, at least 98 immunocyte derived molecules have been found in human
exosomes and 43 immunocyte-derived proteins have been detected on murine immunocyte exosomes
with the potential to modulate immunological functions and regulate exosome stability and trafficking
in vivo. Tables 1 and 2, and Figure 1 summarize our current knowledge of immune-related molecules
found in exosomes.
Table 1. Exosomal proteins of human immunocytes.
Exosomal Proteins Parental Cell Type Reference
Actin; CD9; CD18 (integrin-β2); CD19; CD20; CD24;
CD29(integrin-β1); CD37; CD38; CD45(B220);
CD49d(integrin α-4); CD53; CD54(ICAM-1); CD59; CD63;
CD71; CD80(B7.1); CD81; CD82; CD86(B7.2); FasL; HLA-DR;
Hsp 70; Hsp 90; MHC-I; MHC-II; Moesin; Surface Ig;
Tubulin-α; Tubulin-β
B cell [25,32,37,40,54–56]
17 kD fetal brain protein; Actin; ADF; ADP-ribosylation
factor 3; AIP-1; Albumine humaine; Alix; Annexin I;
Annexin II; Annexin IV; Annexin V; Annexin VI;
Arachidonate-15-lipoxygenase; CD1a; CD1b; CD1c; CD1d;
CD11c; CD19; CD34; CD40; CD41; CD54; CD59; CD61; CD63;
CD80; CD81; CD86; CR3; Cyclophilin A; Cytovillin-2;
Enolase; Enzymes for LT biosynthesis; Ezrin; FasL; MFG-E8;
BAT3; Gelsolin; HLA-DR; Hsp71; Hsp90; IL-15Rα; Integrin;
Major vault protein; MHC-I; MHC-II; MMP-9; Moesin;
Osteopontin; Peptidyl prolylcis-transisomerase A; Protein
GI; Pyruvate kinase M1; Rab7; Rab-GDP dissociation
inhibitor; Ral A; Rap-1b; Cofilin19; Thioredoxin peroxidase 2
Dendritic cell [57–63]
Actin; Alix; c-Cbl; CD2; CD3; CD47; CD63; CXCR4;
Elongation factor α1; FasL; Glyceraldehyde 3-phosphate
dehydrogenase; Hsp90; LFA-1; MHC-I; MHC-II; TCR-β;
TCR-ζ; Thrombospondin-1; Tsg101; Tubulin; Tyrosine
kinases of the Src family
T cell [64–67]
Active tissue factor; CD14; CD18; CD63; CD81; CD9;
Hsp70; Tsg101 monocyte [60,68]
Alix; CD56; CD63; FasL; Fibronectin;Granulysin; Granzymes
A; Granzymes B; Perforin NK cells [69–71]
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Table 2. Exosomal proteins of mouse immunocytes.
Exosomal Proteins Parental Cell Type Reference
C3-fragments; MHC-II B cell [25,47]
Alix;Annexins;CCR7;CD9;CD11c;CD40;CD54;CD71;
CD80;CD86; Cofilin; DC-SIGN molecules;
DEC-205;TLR4;Elongation factor 1α; FasL;
Galectin-3; Heteromeric G protein Gi2α; Hsp73;
Integrin; Mac-1;MFG-E8;MHC-I;MHC-II;MyD88;
PD-L2;Profilin I; Rab 7; Rab 11;Rap 1b; Syntenin;
Thioredoxin peroxidase II; TLR9; TNF; TRAIL
Dendritic cell [27,29,44,48,72–76]
CD54; CD86; LFA-1; MHC-II Bone marrow-derived mouse mast cell [77]
CD25; CD4; FasL; LFA-1;TCR T cell [78]
CD25; CD9;GITR;LAMP-1 Treg cell [79]
Figure 1. Venn diagram showing the distribution of proteins with immunologic function in
immunocyte-derived exosomes from human and murine leukocyte populations. Distribution of
proteins common to different immunocyte lineages is shown. Descriptions of the molecules are shown
in Table 1.
3. NK Cell-Derived Exosomes, Novel Cytotoxic Immune Mediators
NK cells, a subset of large granular lymphocytes, lie at the crossroads of innate and adaptive
immunity. They kill transformed and virally-infected cells without prior immunization, and stimulate
adaptive immunity by secreting pro-inflammatory cytokines and chemokines [80]. A recent study
showed that, following activation, NK cells released exosomes that contained cytotoxic proteins,
such as perforin, granulysin, and granzymes A and B, and mediated tumor cell lysis by activating
caspase pathways, in a manner similar to intact NK cells [69]. Another study identified FasL and
perforin on NK cell-derived exosomes, which displayed cytotoxic activity against several tumor cell
lines [70]. Likewise, perforin, FasL, and TNF-α were detected on exosomes that were derived from
the human NK92 cell line, which promoted cytolysis of melanoma cells in vitro and in vivo [71].
Presensitization may help to improve the cytotoxic activity of NK cell exosomes. Prior exposure
of NKs to neuroblastoma cells increased the secretion of exosomes expressing NK receptors CD56,
NKG2D, and KIR2DL2, and displayed greater cytotoxicity against neuroblastoma tumors relative to
exosomes from naïve NK cells [81]. These studies suggest that NK cell exosomes might be used as
immunotherapeutics for the treatment of tumors and viral diseases (Figure 2).
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Figure 2. Functions of exosomes derived from cytotoxic immune cells. Exosomes derived from CD8+
T cells and natural killer (NK) cells express recognition receptors for antigens, MHC, or damage signals
on target cells and contain cytotoxic mediators, such as perforin, granzymes, and TNF-α that can
eliminate tumors or virus-infected targets. These exosomes can also be used as drug delivery systems
or vaccines in cancer therapy.
4. Exosomes—Nano regulators of Immune Response with Two Faces
Immunocyte exosomes can stimulate or attenuate immune responses, depending on cellular
context, molecular composition, and the microenvironment in which they are produced (Figure 3). For
example, exosomes from mature (mDex) and immature DCs (imDex) have opposing effects on the
immune system. In several studies, immature DCs expressed low levels of co-stimulatory molecules
and promoted immune tolerance, whereas mature DCs expressed high levels of MHC class II, B7.2,
ICAM-1 (CD54), and CD80, reduced levels of MFG-E8 relative to imDex, and had greater potential to
drive antigen-specific T cell proliferation and in vivo immune responses [57,72,82].
Following the treatment of immature DCs with immunomodulatory cytokines IL-10 and IL-4,
the resulting imDex impaired delayed-type hypersensitivity (DTH) and alleviated the severity of
collagen-induced arthritis (CIA) in a murine footpad model [83]. In a rat model of intestinal
transplantation, imDex suppressed the alloreactive T-cell response via up-regulation of IL-10 levels,
and prolonged the survival of intestinal allografts [84]. In combination with the immunosuppressant
rapamycin, imDex inhibited T-cell activation and prolonged the survival of cardiac allografts in vivo,
which was associated with increased splenic CD4+CD25+ regulatory T (Treg) cells and diminished
anti-donor antigen responses [85].
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Figure 3. Effects of immunocyte-derived exosomes in the immune response and the pathogenesis
of disease. Shown is the spectrum of immunocyte exosome functions that have been identified to
date. Immunocyte exosomes stimulate immune responses by potentiating antigen presentation by
dendritic cells (DCs) and B cells, driving CD4+ T cell-mediated help, activating cytotoxic effector
function of NK and CD8+ T cells, or by directly mediating cytolytic activity. On the other hand,
exosomes can be engineered to repress immune function by inhibiting T cell proliferation, inducing
lymphocyte apoptosis, and stimulating Treg development and expansion. The composition and
function of exosomes can be manipulated by treatment of cells with cytokines, such as IL-4 and IL-10,
or expression of molecules such as Fas ligand and CD47. Exosomes are also involved in non-immune
functions, such as chemotaxsis and osteogenic differentiation of stem cells and in pathological processes,
such as athlerosclerosis, tumor metastasis, autoimmune disease, and sequelae of viral infections.
Likewise, Treg-derived exosomes have been shown to maintain immune tolerance. In a rat model
of kidney transplantation, Treg-derived exosomes suppressed T cell proliferation, delayed allograft
rejection, and prolonged allograft survival [86]. In a related study, exosomes that were derived from
CD4+25+ and CD8+25+ Tregs repressed CD8+ T cell mediated immunity against B16 melanoma
cells both in vitro and in vivo, indicating a negative function for Treg exosomes in antitumor immune
responses [79]. These studies suggest that immunocyte-derived exosomes might have deleterious
effects on the immune response to infectious agents and cancer. However, from a therapeutic standpoint,
their immunosuppressive properties may be exploited for the treatment of chronic inflammation,
autoimmune disease, or allograft rejection.
5. Remodeling the Composition and Biological Function of Immunocyte Exosomes: Implications
for Immunotherapy
Extracellular ligand stimulation has been shown to alter the secretion, morphology, and biological
function of immunocyte exosomes. Saunderson, et al. found that CD40 and IL-4 stimulation of
human and murine B cells induced the production of exosomes that were enriched in MHC-I, MHC-II,
and CD45RA (B220), as well as components of the BCR complex [54]. Likewise, TCR crosslinking
induced the production of T cell exosomes that expressed high levels of signaling components, such as
tyrosine kinases of the Src family, c-Cbl, and TCR/CD3 complexes [64].
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Blanchard, et al. showed that exosomes from IL-12-stimulated CTLs were larger than normal and
enriched in immunoregulatory molecules, such as Zap70, Granzyme B, STAT3, and STAT5, which
directly activated bystander naive CD8+ T cells to increase interferon-γ (IFN-γ) and granzyme B
(GZB) levels in the absence of antigen [87]. In a similar study, exosomes from IL-2-stimulated CD3+
T-cells promoted the proliferation of autologous resting CD3+ T cells in the absence of accessory
cells [88]. DCs also responded to activation by stimuli such as LPS by increasing the secretion of
Dex [65]. Interestingly, after LPS stimulation, exosomes secreted by mature DCs were 50- to 100-fold
more likely to induce antigen-specific T-cell activation than imDex in vitro [73].
In addition to an activating role in adaptive immunity, APCs can promote immune tolerance
through the secretion of exosomes with altered levels of antigen presenting and costimulatory molecules.
Ruffner, et al. reported that IL-10 treatment significantly down-regulated the surface expression of
MHC-I, MHC-II, and costimulatory molecules B7-1, B7-2, PD-L1, and PD-L2 on DCs. Exosomes derived
from IL-10-treated DCs suppressed DTH responses by interfering with T cell costimulation [74].
The studies that are cited above demonstrate that ex vivo treatment with cytokines or other stimuli
can shape the molecular and functional repertoire of immunocyte exosomes, tailoring them for specific
functions (Figure 3). Further study is needed to understand how to best manipulate the production
and composition of exosomes to maximize their clinical potential.
6. Modified Exosomes, a More Efficient Vaccine or Immunosuppressive Strategy in
Immunotherapy
Strategies for improving the efficacy of exosome-based immunotherapeutics include (1) direct
loading of antigens onto exosomes ex vivo or (2) genetic or pharmacologic modification of APCs to
engineer exosome composition, improve their yield, and increase their biological activity [52,83,89].
Aline, et al. demonstrated that Dex loaded with toxoplasma gondii antigens accumulated in the spleens
of mice, elicited a Th1-dependent toxoplasma-specific immune response, and conferred protection
against a secondary challenge with toxoplasma [90]. Similarly, Colino, et al. showed that exosomes
from DCs that were loaded with diphtheria toxoid (DT) induced a type 1 (IgG2a and IgG2b) DT-specific
response in vivo [91]. In two recent studies, IL-4 or major birch allergen Betv1—a T-cell-activating
peptide—were expressed in APCs, and the resulting exosomes inhibited the activity of APC and
T cells [92] or induced T-cell proliferation and synthesis of T(H)2-like cytokines (IL-5 and IL-13)
in vitro [55], respectively.
Similarly, tumor-specific antigenic peptides as well as tumor cell lysates have been used to modify
exosomes for the purpose of eliciting antitumor immunity [30,58,93]. In one study, MHC class I
and class II-restricted MART1 tumor peptides loaded onto Dex in acidic conditions bound to MHC
molecules with high affinity and activated CD8+ CTL and CD4+ T-cell responses after processing by
DCs [94]. Similarly, Dex derived from DCs loaded with lysates from chaperone-rich cells (CRCLs) and
GL261 murine glioblastoma tumor cells induced proliferation and CTL activity of CD4+ and CD8+ T
cells and enhanced the production of IL-2 and IFN-γ in vitro. In vivo, the Dex inhibited tumor growth
and prolonged the survival of tumor-bearing mice [95]. In a murine model of hepatocellular carcinoma
(HCC), exosomes that were derived from α-fetoprotein (AFP)-expressing DCs (DEXAFP) decreased
the levels of CD25+ Foxp3+ Tregs and anti-inflammatory cytokines IL-10 and TGF-β, while increasing
CD8+ CTLs and proinflamatory cytokines IFN-γ and IL-2 in the tumor microenvironment, resulting
in prolonged survival of tumor-bearing mice [96]. Rountree, et al. [97] developed an exosome-based
anti-prostate cancer vaccine—MVA-BN-PRO—that contained two chimeric proteins derived from
tumor-associated antigens, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP)
fused to the C1C2 domain of lactadherin, targeting them specifically to the exosome. The vaccine
showed increased immunogenicity and therapeutic efficacy in a PAP-expressing murine prostate
cancer model [97]. Gehrmann, et al. [98] loaded bone marrow-derived dendritic cell (BMDC) exosomes
with α-galactosylceramide (αGC), an invariant NKT (iNKT) receptor ligand, in combination with
the model antigen ovalbumin (OVA), to activate iNKT immune cells. Exosomes that were pulsed
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with both αGC and soluble OVA synergistically induced NK and γδ T-cell innate immune responses,
and also amplified OVA specific T- and B-cell responses. In the B16/OVA murine model of melanoma,
αGC/OVA exosomes decreased tumor growth, increased antigen-specific CD8+ T-cell tumor infiltration,
and increased median survival [98]. Likewise, Dex that were generated from DCs overexpressing
ovalbumin (OVA-Dex) stimulated naive CD8+ T cell proliferation and differentiation into CTL and
induced antigen-specific IgG production [99]. In a related study, OVA-Dex were used to “immunize”
DC via exosome uptake. Dendritic cells immunized with OVA-Dex induced OVA-specific CTL
responses, antitumour immunity, and CD8+ T-cell memory more efficiently than control exosomes
from DCs expressing OVA and more effectively eradicated OVA+ transplanted tumors [75]. Similarly,
CD4+ T cells were immunized with OVA-Dex, and exosomes derived from the immunized CD4+
T cells stimulated a long-term, OVA-specific CD8+ T cell memory response, and immunity against
melanoma cells in vitro and in vivo [100].
Recently, Anticoli, et al. [101]. developed a novel, rapid method of loading antigens into
exosomes by injecting a DNA vector encoding the antigen of interest fused to the C-terminus of
an exosome-anchoring protein into autologous APCs. Antigens of different origins and sizes were
efficiently uploaded into exosomes while using this approach [101]. These studies illustrate the progress
made toward the use of exosomes in immunotherapy through technical advances that increase their
efficacy in stimulating immune responses.
Conversely, other studies have focused on modifying exosomes as an immunosuppressive strategy
for treating autoimmune diseases or prolonging the survival of allografts. Dex derived from DCs
infected with a Fas-L recombinant adenovirus suppressed antigen-specific immune responses and
DTH inflammatory responses in a collagen-induced murine footpad arthritis model [102]. Similarly,
exosomes from Fas-L+ EBV-transformed B cells induced tolerance by Fas-mediated apoptosis of
antigen-specific T helper (Th) lymphocytes [103].
Exosomes from BMDCs that were treated with the anti-inflammatory drug atorvastatin
up-regulated the levels of indoleamine 2,3-dioxygenase (IDO)/Tregs and suppressed autoimmune
responses in rat model of experimental autoimmune myasthenia gravis (EAMG)[104].
The immunosuppressive effect of exosomes was partially reversed by pre-treatment with an anti-FasL
blocking antibody, indicating the involvement of the Fas pathway. Similarly, TGF-β1-loaded Dex
impaired Ag-specific Th1 and IL-17 responses and promoted IL-10 production and the generation of
Tregs in murine models of experimental allergic encephalomyelitis (EAE) and inflammatory bowel
disease (IBD), respectively [105,106].
Dex-immunized T cells also have immunosuppressive effects. Zhang, et al. demonstrated that
exosomes from OVA-Dex-immunized CD4+ T cells directly inhibited CD4+ and CD8+ T responses [78].
Likewise, exosomes derived from CD8+ T cells expressed both OVA-specific T-cell receptors (TCRs)
and Fas ligand. The CD8+ T cell exosomes inhibited CD8+ CTL responses as well as antitumor
immunity against OVA-expressing B16 melanoma cells [107]. These studies suggest that the outcome
of exosome-based vaccines is likely to be context, antigen, and cell-type-dependent. Exosomes
can be engineered to stimulate or suppress the immune response by careful pharmacologic or
genetic manipulation.
7. Clinical Application of Exosome-Based Vaccines
In a clinical trial of stage III/IV melanoma, Escudier, et al. [108]. produced a Dex-based vaccine
by loading tumor antigen MAGE3 peptides onto exosomes that were derived from autologous
DCs. The Dex vaccine was administered to fifteen patients at two doses with no detectable toxicity,
demonstrating the feasibility of large-scale exosome production and the safety of exosome therapy [108].
In a phase I clinical study, autologous MAGE-loaded Dex were administered to 13 patients with
advanced non-small cell lung cancer (NSCLC). Dex therapy was well tolerated and a subset of patients
experienced long-term stability of disease and activation of immune effectors, including NK cells and
MAGE-specific T cells [109]. Further, in a Phase III study where an autologous Dex vaccine (IFN-γ-Dex)
Cancers 2019, 11, 1557 10 of 21
was given to 22 NSCLC patients, median survival was increased and 32% of patients experienced
disease stabilization of more than four months. A subset of treated patients displayed enhanced
NKp30-dependent NK function. Increased NK function and longer progression-free survival in patients
correlated with the expression levels of NKp30 and MHC-II on IFN-γ-Dex vaccine [110]. In another
Phase I clinical trial, autologous, immunocyte-derived exosomes from ascites were combined with
granulocyte-macrophage colony-stimulating factor (GM-CSF) and given to 40 patients with advanced
colorectal cancer. This combination therapy induced beneficial tumor-specific antitumor cytotoxic T
lymphocyte (CTL) responses [111].
When compared to vaccines using intact DCs, clinical trials using exosomes have been limited in
scope, and their potential for eliciting anti-tumor immunity has not been fully evaluated. Whereas
most attempts to use immunocyte exosomes clinically have focused on ex vivo purification of vesicles
from autologous cells, recent studies indicate that exosome-induced immune responses may in fact be
MHC-independent [112]. In addition, as cancer patients often display reduced numbers of circulating
immune cells as well as impaired lymphocyte and DC function, autologous immunocytes might be
suboptimal sources for the production of exosome-based therapeutics. In light of these findings,
Samuel and Gabrielsson have proposed that allogeneic exosomes may be more effective, as they are
able to induce robust and wide-ranging anti-tumour immune responses in vivo [113].
Accordingly, studies are underway directly comparing the relative efficacy of intact DCs and
Dex in stimulating anti-tumor immune responses. Currently, there are at least six ongoing or recently
completed clinical trials using immunocyte exosomes as vaccines or biomarkers of immune function
in cancer.
8. Roles for Immunocyte Exosomes in Pathophysiologic Processes, Inflammation, Tissue
Remodeling, and Response to Injury
In addition to their antigen presentation functions, immunocyte exosomes have been shown to
regulate tumor growth and metastasis, leukocyte trafficking and inflammation, and the pathogenesis
of infectious diseases (Figure 3). T cell-derived exosomes have been shown to promote the invasion
and metastasis of melanoma and lung cancer by increasing matrix metalloproteinase-9 (MMP-9)
expression through Fas/FasL-dependent ERK and NF-kB activation [114]. Interestingly, the secretion
of Fas-L+ T cell-derived exosomes was controlled by diacylglycerol kinase-α (DGK-α), suggesting
that pharmacologic regulators of DGK-α can modulate the biosynthesis and release of toxic exosomes
in vivo [66,115]. Likewise, Yang, et al. found that oncogenic miRNAs in exosomes derived from
tumor-associated macrophages were delivered to breast cancer cells and enhanced their invasive
properties in vitro [68].
In the tumor microenvironment, exhausted CD8+ T cells (PD1+TIM3+) secreted exosomes, which
impaired normal CD8+ T cell proliferation, activation, and the production of cytokines, and may
interfere with antitumor immunity [116]. On the other hand, CTL-derived exosomes have also been
shown to enhance the activation of low-affinity CTLs that play an important role in controling of
intracellular pathogens and cancers [117]. Lymphocyte exosomes can either activate or impair antitumor
immunity, depending upon cellular context and the conditions of the tumor microenvironment.
Macrophage exosomes have also been shown to have tumor-promoting effects. Lan, et al.
demonstrated that M2-polarized macrophages could promote colon cancer invasion and metastasis
through the delivery of micro RNAs miR-21-5p and miR-155-5p that target the antimetastatic gene
BRG1 [118]. In contrast, others have shown that exosomes from M1 polarized macrophages induced
exit of breast cancer stem cell from quiescence and increased their migratory capacity, whereas M2
macrophage exosomes maintained cancer stem cell dormancy [119]. These data suggest that exosomes
from M1 and M2-polarized macrophages differentially regulate cancer stem cell mobilization and
epithelial to mesenchymal transition (EMT). Biological targeting agents that alter the M1/M2 balance
may therefore reprogram macrophage exosomal function in the tumor microenvironment to favor
inhibition of EMT and metastasis.
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Immunocyte exosomes also impact vascular biology and disease. CD4+ T cell exosomes
enhanced cholesterol accumulation and induced the production of the proinflammatory cytokine
TNF-α in cultured human monocytes, which suggests that T cell exosomes might play a role in
the pathogenesis of atherosclerosis [120]. T-cell-derived exosomes have been shown to contain
thrombospondin-1 and its receptor CD47, which promote endothelial cell responses to vascular
endothelial growth factor (VEGF) and accelerate tube formation via VEGF signaling, which suggests a
role for exosomes in CD47-dependent tumor angiogenesis [67]. In addition, Aharon, et al. have shown
that monocyte-derived exosomes induced procoagulant production and apoptosis of endothelial cells,
and accelerated endothelial thrombogenicity, consistent with a role in endothelial cell dysfunction that
is associated with inflammatory diseases [121].
While exosomes can play an important role in antigen presentation and lymphocyte activation,
they also regulate other fundamental immunologic processes. In several studies, cytokines have
been detected in immunocyte exosomes, which impact inflammatory responses, innate immunity,
and lymphocyte development. Gao, et al. have shown that Dex contain TNF-α, which may play a role
in endothelial inflammation and atherosclerosis via membrane TNF-α- induced NF-κB activation [122].
Membrane-bound IL-1β was found on exosomes that were secreted from DCs and macrophages and
may play a role in inflammation [123,124]. Wang, et al. reported that TGF-β-containing exosomes
derived from thymic cells skewed T cell development in favor of Foxp3+ Tregs, stimulated the
differentiation of CD4+CD25 T cells into effector Tregs and induced their proliferation in vitro and
in vivo [125]. Another study showed that macrophage exosomes contain miR-223, which can be
efficiently transported to monocytes and induce macrophage differentiation [126].
Some critical NK cell activators, including TNF-α, IL-15Rα, and NKG2D ligands, were also found
on the surface of human Dex. It has been shown that Dex promote NK cell proliferation and drive NK
activation and IFN-γ secretion [76,127]. Further, exosomes that were derived from human macrophages
and DCs contained pro-inflammatory leukotrienes (LTs) as well as LT biosynthesis enzymes, which
suggests that they can promote inflammation and play a role in the pathogenesis of asthma [59].
An important component of immunity and response to injury is the migration of effector cells to
sites of action in vivo. Chemotactic eicosanoids have been identified in macrophage and DC-derived
exosomes, which promoted granulocyte migration and recruitment, suggesting that exosomes play a
role in leukocyte trafficking [59]. Conversely, Dex which express the chemokine receptor CCR7 have
been shown to home to the spleen in response to splenic chemotactic factors CCL19 and CCL21 [128].
Immunocyte exosomes have also been show to regulate stem cell-dependent tissue regeneration.
Exosomes from monocytes treated with LPS up-regulated osteogenic gene expression in mesenchymal
stem cells (MSC) and induces their osteogenic differentiation [60]. Similarly, intestinal epithelial
homoeostasis depends on Wnt/β-catenin signaling crosstalk between the crypt intestinal stem cells (ISC)
and the surrounding stromal cells. Saha, et al. found that Wnt was expressed on macrophage-derived
exosomes, which could rescue intestinal stem cells and enhance their survival after radiation injury [129].
In a recent neurological study, environmental enrichment (EE) was shown to play a role
in neuroprotection in an exosome-dependent manner. Investigators found that serum-derived
immunocyte exosomes that were isolated from EE-treated rats significantly increased myelin content,
oligodendrocyte precursor (OPC) and neural stem cell levels, and reduced oxidative stress (OS) in vitro.
Micro RNA profiling revealed that miR-219 was enriched in rat EE exosomes, which was necessary
and sufficient for promoting OPC differentiation into myelinating cells [130]. Likewise, following
the treatment of DCs with IFN-γ, Dex carrying specific microRNAs increased baseline myelination,
reduced oxidative stress, and improved remyelination in acute autoimmune lysolecithin-induced
demyelination, which illustrates the potential of IFN-γ-Dex in the treatment of multiple sclerosis and
other demyelinating syndromes [131].
Immunocyte exosomes have also been shown to aid in the repair of cadiovascular injury. Exosomes
from DCs co-incubated with hypoxic, necrotic cardiomyocytes were preferentially recruited to the
spleen and taken up by CD4+ T cells in mice. Dex increased TNF-α and IFN-γ production in splenic T
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cells and improved cardiac function in a murine model of myocardial infarction (MI), which suggests a
novel strategy for the treatment of MI using Dex-based therapeutics [132].
Taken together, these findings suggest that immunocyte exosomes might not only function in
immune modulation and leukocyte migration, but may also regulate stem cell mobilization, tissue
remodeling, and wound healing.
In the context of infectious diseases, immunocyte exosomes have been implicated in the response
to and sequelae of both bacterial and viral infections. In an animal model of sepsis, Dex containing
milk fat globule EGF-factor-8 (MFG-E8), a macrophage surface protein that mediates phagocytosis of
apoptotic lymphocytes, decreased plasma TNF-α and IL-6 levels and attenuated inflammation-induced
septic shock [133]. In the life cycle of several viruses, exosomes promote viral infection and transmission.
Several studies have demonstrated that HIV buds not only from the plasma membrane, but also from
lipid rafts in T-cells and macrophages suggesting that viruses can hijack the exosomal pathway to
promote viral particle production and dissemination [134,135]. Other studies suggest that human
hepatitis C virus might also use a similar strategy to spread in vivo [136].
The consequences of HIV infection also include sequelae that are associated with altered
immunocyte exosomes. The treatment of monocytes with IFN-α and LPS to mimic the conditions
in the blood of AIDS patients induced the production of exosomes with an altered miRNA profile,
which induced the expression of ICAM-1, chemokine ligand (CCL)-2, and IL-6 in endothelial cells [137].
These findings might explain the long-term cardiovascular inflammation in HIV patients. Elucidating
the function of exosomes in disease pathogenesis may reveal underlying disease mechanisms and
provide targets for the development of therapeutics that block the deleterious effects of exosomes.
9. Conclusions and Future Directions
Much effort has been devoted to the development of immunocyte exosomes as therapeutics. They
have critical advantages over small molecule pharmacologics and antibody-based agents in that they
are directly derived from cell membranes and retain properties of intact cells; they can transfer entire
activated signaling pathways and large macromolecular complexes in lipid rafts that present antigens
and trigger lymphocyte activation in much the same manner as intact immunocytes. Exosomes can be
designed with a high degree of target specificity by engineering them to express ligands for tissue or cell
type-specific receptors. Furthermore, their unique lipid composition and resistance to phagocytosis and
complement-mediated lysis provide exosomes with protection against degradation in the circulation,
which greatly enhances their stability in vivo and protects highly unstable cargo, such as micro RNAs.
Exosomes are also stable ex vivo and retain their biological activity after cryogenic storage. Thus,
they are uniquely suited for development as therapeutics. Immunocyte exosomes can modulate
biological processes as diverse as anti-tumor immunity, stem cell mobilization, and tissue remodeling,
which suggests a wide range of clinical applications. Some fundamental challenges to realizing the
clinical potential of exosomes still remain, such as maximizing biological function, increasing yield,
and controlling their molecular composition. Much of the exosome research over the last several years
has focused on overcoming these hurdles.
Dendritic cell-derived exosomes with enhanced biological activity have been generated by
direct pulsing of purified exosomes with antigenic peptides, cell lysates, or peptide/MHC complexes,
the pre-treatment of DCs with cytokines, such as IFN-γ, to increase the expression of co-stimulatory
molecules and pro-inflammatory micro RNAs, ectopic overexpression of antigens, co-stimulatory
proteins or adhesion molecules, stimulation of exosome production with TLR4 ligands, and redirected
subcellular localization of antigens to the exosome. The enhanced efficacy of Dex can also be achieved
by targeting exosomes to secondary lymphoid organs via CCR7-mediated chemotaxis to CCL19 and
CCL21 ligands produced by leukocytes in the spleen.
In addition, Dex can also stimulate the innate immune response via NK-activating molecules,
such as IL-15 receptor, TNF-α, and NKG2D ligands, which have been shown to activate NK cell
proliferation and effector function. Further, loading Dex ex vivo with iNKT ligands, such as
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galactosylceramide, stimulates pro-inflammatory cytokine production by iNKT cells, which drives
proliferation and effector function of NK cells. B and T cell exosomes have been similarly engineered
to stimulate immune responses. Covalent binding of C3 complement fragments on B cell exosomes
promotes immune activation via interactions with g-protein-coupled receptors on T cells. Likewise,
exosomes from IL-2-stimulated T cells potentiate activation of CD3+ T lymphocytes in the absence
of APCs. Immunocyte exosomes also package pro-inflammatory and chemotactic mediators that
modulate lymphocyte activation and leukocyte migration in vivo. Likewise, exosomes from DCs and
macrophages contain the machinery for the biosynthesis of leukotriens and they can be stimulated to
produce chemotactic eiconasoids that induce the migration of neutrophils to sites of infection.
In addition to antigen presentation, immunocyte exosomes can also execute effector functions,
such as cell-mediate cytotoxicity. Natural killer cell-derived exosomes express NK-related receptors
such as NKG2D, FasL, KIR2DL2, as well as cytotoxic factors (perforin, granulysin, granzymes A
and B, and TNF-α) that contribute to the lysis and elimination of tumors or virus-infected cells.
Likewise, exosomes that are derived from antigen-specific CD8+ CTLs might also target tumor cells
for destruction or be used as a delivery system for anti-tumor drugs due to the antigen specificity of
their T cell receptors [138].
On the other hand, several studies have shown that immunocyte exosomes can suppress adaptive
immunity, suggesting that they might be developed as therapeutics to treat autoimmune diseases or to
prevent rejection of organ transplants. Exosomes derived from immature DCs or DCs pre-treated with
anti-inflammatory cytokines, such as IL-10 or overexpressing IL-4, can suppress T cell activation and
induce immune tolerance. Statin treatment of DCs, which reduces the expression of co-stimulatory
molecules, and loading of Dex with TGF-β also have been shown to skew the activity of exosomes toward
an immunosuppressive phenotype. Exosomes from DC’s, B, or T cells can induce immunosuppression
by various other mechanisms, including Fas-mediated apoptosis and downregulation of MHC-peptide
complexes. These studies underscore how knowledge of exosome biogenesis dovetails with the genetic
and pharmacologic engineering of more potent exosomes for therapeutic applications.
Immunocyte exosomes have also been shown to regulate processes beyond the immune response.
Recent studies have demonstrated the activity of macrophage exosomes on wound healing, osteogenesis,
and macrophage development. Likewise, DC-derived exosomes contain osteopontin, chemotactic
factors and MMP-9, which may play a role in tissue regeneration mediated by mesenchymal stem
cells. Surprisingly, macrophage exosomes can rescue tissue stem cells from radiation injury via Wnt
signaling, suggesting that they can be therapeutically used as radioprotectors in cancer therapy or
following accidental radiation exposure.
Immunocyte exosomes may also have deleterious pro-inflammatory or tumor-promoting activity.
Monocyte exosomes have been shown to possess pro-coagulant properties that might contribute to
endothelial cell-mediated thrombosis, T cell exosomes can promote tumor angiogenesis by activating
VEGF signaling and induce cancer cell invasion by increasing the production of MMP-9, and exosomes
from polarized macrophages can transfer MiRNAs to tumor cells that target anti-metastatic genes.
CD4+ T cell exosomes can induce TNF-α in monocytes, which may contribute to atherosclerosis.
Likewise, DC exosomes contain TNF-α, which can also contribute to atherosclerotic disease. Thus,
immunocyte exosomes represent an unusually versatile class of structures that can be engineered
to perform a wide range of functions within and beyond the immune system. However, with this
versatility comes the caveat that exosome composition and their interactions with other biological
systems must be carefully considered to avoid unwanted, deleterious off-target side effects.
Currently, the development of immunocyte exosomes as vaccines or targeted therapeutics for the
treatment of cancer or autoimmunity is still in its early stages. In many trials, exosome vaccines have
displayed low activity when compared to intact APCs [93,139]. Possible strategies to improve their
efficacy include enhanced exosome purification, loading of more potent antigens, using combinations
of antigens, potentiating the vaccines using adjuvants or cytokine treatments, and modulating
the efficiency of exosome transport in vivo [43,140]. Exosome-based vaccines can also be used in
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combination with immunoadujvant therapies that synergistically modulate lymphocyte helper or
effector function. It is important to note that immunocyte exosomes in early clinical trials displayed no
serious toxicity, which indicates that wider clinical use of exosome-based therapies would likely show
minimal side effects.
Recent advances in our understanding of exosome biogenesis raise the intriguing possibility
that exosome production and function can be modulated in vivo. The stimulation of P2X7R
adenosine receptors on macrophages and DCs increases the production of exosomes expressing
the pro-inflammatory mediator IL-1β, synthesis of chemotactic eiconasoids can be induced in Dex and
macrophage-derived exosomes by treatment with Ca+ ionophore and arachadonic acid, the production
of immunosuppressive Fas+ T cell exosomes is regulated by the activity of diacyglycerol kinase-alpha,
and the overall yield of Dex can be increased by TLR4 activation in DCs. Thus, it might be possible to
modulate the composition, yield, and biological activity of immunocyte exosomes in vivo using small
molecule pharmacologics that regulate exosome biosynthetic pathways, avoiding the technical pitfalls
of production, purification, and manipulation of exosomes ex vivo.
Recent exciting advances have placed the field in a position to combine genetic and pharmacologic
enhancement of exosome activity with new technologies that increase their purity and yield. A novel
method has been reported for preparing exosomes in increased quantities by forcing cells through a
screen mesh with apertures that select for vesicles of the appropriate size [141]. Further, a microfluidic
cell culture platform has been described that can produce exosomes of defined composition on a large
scale by using a 3D-printed microfluidic chip containing chambers for all steps in the process of exosome
production and purification [142]. These technologies might obviate much of the technical issues that
are involved in exosome production, such as poor yield, low purity, and molecular heterogeneity,
which have frustrated efforts to develop exosomes as therapeutic tools.
The rapid pace of advances in exosome biology and clinical application have brought us to the cusp
of a new era in therapeutics with the potential to impact a myriad of diseases and biological processes.
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